Non-invasive Prenatal Testing Market Report 2026

Non-invasive Prenatal Testing Market Overview

• Non-invasive Prenatal Testing market size has reached to $6.27 billion in 2025 • Expected to grow to $12.37 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: The Role Of Increasing Maternal Age In Driving Non-Invasive Prenatal Testing Market Growth • Market Trend: Advancing Linked SNP Technology To Improve The Accuracy And Accessibility Of Fetal Genetic Screening • North America was the largest region in 2025 and Western Europe is the fastest growing region.

What Is Covered Under Non-invasive Prenatal Testing Market?

Non-invasive prenatal testing is a test in which blood from the mother is drawn and tested for possible abnormalities in the patient. Non-invasive prenatal testing kits and equipment are used to diagnose genetic abnormalities, mainly chromosome defects, in fetuses in the first trimester of pregnancy. The main types of non-invasive prenatal testing are consumables, and instruments. Consumables are products that are used up or depleted throughout their use. The various instrument used are NGS systems, PCR instruments, microarrays, ultrasound devices, and others (centrifuges, UV systems, incubators, microscopes) and the different consumables include assay kits and reagents, disposables. The applications involve trisomy, microdeletion, genetics, Rh factor that are used by hospitals and diagnostic labs.

What Is The Non-invasive Prenatal Testing Market Growth Forecast?

The non-invasive prenatal testing market size is expected to see rapid growth in the next few years. It will grow to $12.37 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising adoption of non-invasive prenatal testing globally, increasing investment in advanced sequencing technologies, expansion of hospital and diagnostic lab networks, growing demand for early genetic screening, advancing integration of ai and data analytics in prenatal diagnostics. Major trends in the forecast period include rising adoption of ai-based genetic analysis, increasing use of ngs and pcr systems for prenatal testing, growing implementation of cloud-based data management in diagnostics, expanding deployment of high-throughput screening technologies, advancing integration of personalized prenatal risk assessment.

Global Non-invasive Prenatal Testing Market Segmentation

1) By Type: Consumables, Instruments 2) By Application: Trisomy, Microdeletion, Genetics, Rh factor 3) By End User: Hospital, Diagnostic Labs Subsegments: 1) By Consumables: Assay Kits, Reagents, Disposables 2) By Instruments: Next-Generation Sequencers (NGS), Polymerase Chain Reaction (PCR) Systems, Ultrasound Devices

What Is The Driver Of The Non-invasive Prenatal Testing Market?

Increasing maternal age is expected to drive the growth of the non-invasive prenatal testing market going forward. The increase in maternal age is influenced by factors such as pursuing education, career, financial stability, personal choice, delayed marriage, improved contraception, and societal changes, allowing women to make more informed decisions about family planning. As women delay childbirth, there's a higher risk of chromosomal abnormalities, prompting more expectant mothers to opt for NIPT to assess the health of their pregnancies. For instance, in March 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, the average age of mothers at their first birth rose to 27.5 years, up from 27.4 in 2022, marking yet another record high for the nation. Therefore, increasing maternal age will continue to propel the growth of the non-invasive prenatal testing industry.

Key Players In The Global Non-invasive Prenatal Testing Market

Major companies operating in the non-invasive prenatal testing market are F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Inc., Agilent Technologies Inc., BGI Diagnosis Co Ltd., Berry Genomics Co, LifeCodexx AG, Myriad Genetics Inc., NIPD Genetics Co Ltd., Sequenom Inc., Annoroad Gene Technology Co Ltd., Centogene AG, Counsyl Inc., EUROFINS Genoma Group, Eurofins Scientific SE, Next Biosciences, Premaitha Health Plc, Ariosa Diagnostics Inc., Yourgene Health PLC, GE Healthcare Technologies Inc., Koninklijke Philips NV, Thermo Fisher Scientific Inc., Pacific Biosciences of California Inc., QIAGEN NV, MedGenome Labs Ltd., Progenity Inc., Beijing Genomics Institute

Global Non-invasive Prenatal Testing Market Trends and Insights

Major companies operating in the non-invasive prenatal testing (NIPT) market are focusing on developing advanced solutions such as linked-SNP (single nucleotide polymorphism) technology to improve diagnostic precision, strengthen the detection of complex genetic cases, and minimize reliance on paternal samples. Linked-SNP technology evaluates single-gene variants by analyzing genetically linked markers across the genome to infer inheritance patterns, enabling more accurate identification of challenging conditions such as homozygous mutations. For instance, in August 2025, Natera, a US-based cell-free DNA (cfDNA) testing and precision medicine company, launched Fetal Focus, a NIPT for inherited single-gene disorders that directly screens the fetus using only maternal blood when the biological father is unavailable. The test targets five genes are CFTR, SMN1, HBA1/HBA2, and HBB, and is supported by data from the EXPAND clinical trial. In its first readout (n=101), Fetal Focus demonstrated 91% sensitivity and successfully detected all five homozygous variant fetuses, underscoring the strength of its linked-SNP–based approach in delivering noninvasive and clinically meaningful risk assessment.

What Are Latest Mergers And Acquisitions In The Non-invasive Prenatal Testing Market?

In January 2024, Natera, Inc., a US-based clinical genetic testing company acquired reproductive health assets from Invitae for $42.5 million. With this acquisition, Natera Inc, aims to enhance its offerings in non-invasive prenatal and carrier screening which are critical components of reproductive health. Invitae is a US-based biotechnology company that provides non-invasive prenatal testing services.

Regional Outlook

North America was the largest region in the non-invasive prenatal testing market in 2025. Western Europe was the second largest region in the non-invasive prenatal testing market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-invasive Prenatal Testing Market?

The non-invasive prenatal testing market includes revenue earned by ultrasound detection, fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests, and biochemical screening tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-invasive Prenatal Testing Market Report 2026?

The non-invasive prenatal testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-invasive prenatal testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.